Intercept Pharmaceuticals
Intercept Pharmaceuticals[edit]
Intercept Pharmaceuticals is an American biopharmaceutical company that specializes in the research, development, and commercialization of novel therapeutics for treating progressive non-viral liver diseases. With a focus on liver health, the company has made strides in addressing unmet medical needs in hepatology.
Overview[edit]
Founded with the mission of shaping the future of liver health, Intercept Pharmaceuticals stands at the forefront of hepatic medical research. By identifying and targeting the underlying causes of liver diseases, it strives to advance patient care in areas of significant medical need.
History[edit]
Established in 2002, the inception of Intercept Pharmaceuticals was driven by a shared vision among its founders to challenge and transform the hepatic healthcare paradigm. Over the years, the company has emphasized innovative approaches to liver disease treatment, consistently bridging gaps in hepatological care.
Core Therapeutics[edit]
- Ocaliva (obeticholic acid): Intercept's flagship product, Ocaliva, is an agonist of the farnesoid X receptor (FXR) and is used in the treatment of primary biliary cholangitis (PBC). Its introduction marked a significant advancement in the therapeutic options for this chronic liver disease.
- Pipeline Drugs: The company maintains an active pipeline with drugs aimed at treating other liver conditions, including non-alcoholic steatohepatitis (NASH) and biliary atresia, to name a few.
Research and Development[edit]
Intercept's R&D operations stand on a foundation of rigorous scientific research and a deep understanding of liver biology. Collaboration with global experts, continuous clinical trials, and an unyielding commitment to patient well-being underpin the company's product development philosophy.
Partnerships and Collaborations[edit]
Emphasizing the strength of collaboration, Intercept Pharmaceuticals has formed multiple strategic partnerships with research institutions, healthcare organizations, and other pharmaceutical companies. These synergistic alliances aim to accelerate drug development and enhance patient accessibility.
See Also[edit]
References[edit]
- [1] "Company Overview". Intercept Pharmaceuticals.
- [2] "Intercept Pharmaceuticals: A Journey of Innovation". Intercept Pharmaceuticals.
- [3] "Product Pipeline and R&D". Intercept Pharmaceuticals.
 | This corporation or company article is a stub. You can help WikiMD by expanding the page. |
-
Logo of Intercept Pharmaceuticals
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
